<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03852381</url>
  </required_header>
  <id_info>
    <org_study_id>18-5864</org_study_id>
    <nct_id>NCT03852381</nct_id>
  </id_info>
  <brief_title>Mechanisms and Outcome-Prognostication for Paresthesia-based and -Free Spinal Cord Stimulation</brief_title>
  <acronym>MOPPStim</acronym>
  <official_title>Mechanisms and Outcome-Prognostication for Paresthesia-based and -Free Spinal Cord Stimulation in Patients With Persistent Neuropathic Pain: the MOPPStim Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MSH-UHN AMO Innovation Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Spinal cord stimulation (SCS) relies on stimulation of pain-relieving pathways in the spinal
      cord to treat chronic neuropathic pain. Traditional paresthesia-based SCS (PB-SCS) relies on
      providing analgesia through stimulation of spinal cord dorsal columns but it is often
      associated with attenuation of analgesic benefit and lack of acceptance of paresthesias.
      Recently introduced three different paresthesia-free (PF-SCS) modes of stimulation aim to
      overcome limitations of PB-SCS. Several questions regarding PB and PF SCS modes remain
      unanswered including the mechanisms of therapeutic benefit, criteria for selecting patients
      likely to benefit, and long-term outcomes. A concerted effort is required to understand and
      optimize utilization of SCS. This project has the twin goals of using neuroimaging techniques
      to understand mechanisms that underlies analgesic benefit from PB/PF-SCS modes and to
      identify criteria for selecting patients based on monitoring of pain and its related domains
      in patients undergoing SCS trials. Achieving these objectives will increase probability of
      analgesic benefit while minimizing adverse effects and knowledge gains from this study will
      be applicable to other therapies for chronic pain conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Over 7 million Canadians suffer from chronic pain with 1 in 4 patients having neuropathic
      pain (NP), a condition caused by injury to nerves in the body. NP tends to have an extremely
      unpleasant character, severe intensity, and a persistent unremitting course. Conventional
      medical management (CMM) is often ineffective in relieving NP in majority of these patients.
      Paresthesia-Based Spinal Cord Stimulation (PB-SCS) has been used to treat NP but it has
      limitations in terms of preserving analgesic benefit and it is often associated with adverse
      effects. Recently introduced Paresthesia-Free SCS (PF-SCS), available at all tertiary level
      pain centers, has the potential to overcome these limitations but knowledge gaps remain in
      understanding and applying this modality.

      The study design will be a prospective, exploratory study with randomization of order of no
      stimulation with novel modes of PF-SCS during the SCS trial and blinding of subjects (as per
      clinical standard of care) and outcome assessors. Participants with appropriate indications
      for trial of SCS with novel paresthesia-free modes will be enrolled. Baseline demographic and
      pain-related data including opioid intake in Oral Morphine Equivalents Per day in mg (OMED)
      will be collected. Pre-SCS trial neuroimaging (fMRI, MEG) and QST will be performed to
      establish parameters for future comparisons. Data on physical activity and sleep will be
      collected using actigraphy, as per standard of care. Data on pain and its related domains
      will be collected using validated questionnaires on the Manage My Pain app, in which all
      questionnaires administered are part of the patient's clinical standard of care. Ninety
      subjects will undergo a percutaneous trial of SCS that will last 12 days and the trial will
      be divided into three phases. All subjects will trial a conventional paresthesia-based SCS
      mode in the first four days of the trial. Subjects will then proceed the next four days (day
      5-8) with no (placebo) stimulation, followed by one of the three novel PF-SCS modes (Burst,
      High Frequency, High Density) for the last 4 days of the trial. This process is currently
      adopted for all patients receiving SCS as standard of care. Neuroimaging (fMRI, MEG) and QST
      will be performed at the end of the SCS trial. Subjects who achieve significant reduction in
      pain, disability and sleep disturbance questionnaire scores with one of the novel PF-SCS
      modes will be offered percutaneous implantation of SCS system 4 to 6 weeks after the end of
      the trial using the novel PF-SCS mode they experienced during the trial. MEG and QST will be
      performed and data from validated questionnaires on the Manage My Pain app will be collected
      at 6 months after implantation.

      Use of fMRI (functional Magnetic Resonance Imaging), MEG (Magnetoencephalography), and QST
      (Quantitative Sensory Testing) in this study will help improve understanding of the
      alteration in brain in NP and the analgesic action of PB/PF-SCS. Validation of wearable
      technology and of app-based digital platforms will allow these available but
      infrequently-used modalities to improve success of analgesic treatments in patients with
      chronic pain. Healthcare systems will benefit through efficient use of resources to treat
      chronic pain made possible by understanding what works, who does it work for, and how to
      predict analgesic benefit.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 16, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in neuronal activity with the novel PF-SCS modes as detected by fMRI and MEG</measure>
    <time_frame>12 days after the initiation of the SCS trials )</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in neuronal activity with the novel PF-SCS modes as detected by fMRI and MEG</measure>
    <time_frame>6 months after the initiation of the SCS implants</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To measure long-term outcomes of novel PF-SCS modes including intensity and quality of pain, physical and psychological functioning, and patients' global impression of change</measure>
    <time_frame>6 months after the initiation of the SCS implants.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in sensory threshold with the novel PF-SCS modes as detected by QST</measure>
    <time_frame>6 months after the initiation of the SCS implants</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To measure incidence of more than 50% reduction in pain intensity scores in patients with NP syndromes with novel modes of SCS</measure>
    <time_frame>Six months after implantation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To correlate data on physical activity as measured by an accelerometer during trials of novel SCS modes with data obtained from validated questionnaires</measure>
    <time_frame>12 days after the initiation of the SCS trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To correlate data on sleep as measured by an accelerometer during trials of novel SCS modes with data obtained from validated questionnaires</measure>
    <time_frame>12 days after the initiation of the SCS trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To measure incidences of analgesic failure (as indicated with less than 50% reduction in pain intensity scores) and adverse effects of PF-SCS</measure>
    <time_frame>Six months after implantation.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Neuropathic Pain</condition>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Spinal Cord Stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At baseline, the following data will be recorded: standard-of-care questionnaire scores, neuroimaging (fMRI, MEG), psychophysical testing (QST), accelerometer sleep and activity data.
The trial will proceed as follows:
Day 1-4: Paresthesia-based SCS (PB-SCS)
Day 5-8: No SCS (placebo)
Day 9-12: PF-SCS
Neuroimaging and psychophysical testing will be conducted at the end of the trial, and will be assessed 6-months post-implantation of the SCS device along with adverse effects. A decision to implant the SCS system will be made based on reduction of patient pain intensity by 50% in PB-SCS and/or PF-SCS modes, but not with placebo SCS.
Based on the response in the trial, the patient will either not be a candidate for an SCS implant, or they will receive one of the four modes upon implantation (PB-SCS, or one of the three PF-SCS: Burst, High Frequency, High Density).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Spinal Cord Stimulation</intervention_name>
    <description>Paresthesia-based SCS(PB-SCS), with stimulating frequencies between 30 to 80 Hz that confer a tingling sensation. Three different paresthesia-free SCS (PF-SCS) modes that use frequencies in the range of 400-10,000 Hz include Burst, High Frequency stimulation at 1.2 kHz and High Density stimulation at 400 Hz.</description>
    <arm_group_label>Spinal Cord Stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adults, 18 - 80 years of age, with refractory neuropathic pain (as per clinical
             features and DN4 score &gt; 3/10) in back and or lower limbs for more than 3 months
             following lumbar spine surgery

          2. Severity of pain &gt; 3/10 on NRS and ODI score for disability &gt;40/100; and

          3. Pain refractory to conventional medical management tried for at least 3 months.

        Exclusion Criteria:

          1. Age &lt; 18 or age â‰¥ 80 years;

          2. Previous trial or implantation of SCS system;

          3. Procedural contraindications to SCS including extensive thoracolumbar spine surgery,
             moderate-to-severe central canal stenosis, coagulopathy, local or systemic infection;

          4. Pregnancy;

          5. Opioid dose &gt; 200 mg OMED;

          6. Psychiatric or psychological disorder likely to impact perception of pain;

          7. Inability to comply with the study interventions or evaluate treatment outcomes;

          8. Mechanical spine instability as per flexion/extension lumbar X-rays;

          9. Ongoing litigation issues related to the pain; and

         10. Concomitant peripheral neuropathy or myopathy or central neuropathic pain (e.g.
             post-stroke pain).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anuj Bhatia, MD FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anuj Bhatia, MD FRCPC</last_name>
    <phone>(416) 603-5800</phone>
    <phone_ext>6136</phone_ext>
    <email>anuj.bhatia@uhn.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jamal Kara</last_name>
    <phone>(416) 603-5800</phone>
    <phone_ext>6237</phone_ext>
    <email>jamal.kara@uhn.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anuj Bhatia, MD FRCPC</last_name>
      <phone>(416) 603 5800</phone>
      <phone_ext>6136</phone_ext>
      <email>anuj.bhatia@uhn.ca</email>
    </contact>
    <contact_backup>
      <last_name>Jamal Kara</last_name>
      <phone>(416) 603 5800</phone>
      <phone_ext>6237</phone_ext>
      <email>jamal.kara@uhn.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>December 31, 2018</study_first_submitted>
  <study_first_submitted_qc>February 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2019</study_first_posted>
  <last_update_submitted>May 17, 2019</last_update_submitted>
  <last_update_submitted_qc>May 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Health Network, Toronto</investigator_affiliation>
    <investigator_full_name>Anuj Bhatia</investigator_full_name>
    <investigator_title>Director, Anesthesia Chronic Pain Clinical Services</investigator_title>
  </responsible_party>
  <keyword>Spinal Cord Stimulation</keyword>
  <keyword>Burst Stimulation</keyword>
  <keyword>High Frequency Stimulation</keyword>
  <keyword>High Density Stimulation</keyword>
  <keyword>fMRI</keyword>
  <keyword>MEG</keyword>
  <keyword>QST</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Paresthesia</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

